Pfizer has announced the discontinuation of its oral GLP-1 pill, danuglipron, intended for obesity treatment, following reports of liver injury in a patient during clinical trials. This decision marks a significant setback for the pharmaceutical giant as it aimed to compete in the weight-loss drug market. The news has resonated across the industry, leading to stock rallies for rival companies such as Eli Lilly and Novo Nordisk. Analysts are now speculating about the implications for Pfizer’s future in the obesity drug sector and the potential impact on its valuation. The discontinuation of this $130 billion weight-loss project raises questions about the company’s next steps in this competitive field.